Surrozen reports Q2 2026 results, plans SZN-8141 IND filing by Q3 end
The company also targets a year-end 2026 start for its DUET trial in diabetic macular edema, with initial data expected in the second half of 2027.
SEC filing
Latest
1 story
Sign in